nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—Dehydration—Cisplatin—esophageal cancer	0.00236	0.00394	CcSEcCtD
Pergolide—Oesophagitis—Capecitabine—esophageal cancer	0.00236	0.00394	CcSEcCtD
Pergolide—Petechiae—Methotrexate—esophageal cancer	0.00234	0.0039	CcSEcCtD
Pergolide—Neoplasm—Capecitabine—esophageal cancer	0.00233	0.00389	CcSEcCtD
Pergolide—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00232	0.00387	CcSEcCtD
Pergolide—Hypokalaemia—Cisplatin—esophageal cancer	0.00231	0.00386	CcSEcCtD
Pergolide—Apnoea—Methotrexate—esophageal cancer	0.00227	0.00378	CcSEcCtD
Pergolide—Abnormal vision—Capecitabine—esophageal cancer	0.00225	0.00376	CcSEcCtD
Pergolide—Mental disability—Capecitabine—esophageal cancer	0.00224	0.00374	CcSEcCtD
Pergolide—Sepsis—Capecitabine—esophageal cancer	0.00224	0.00374	CcSEcCtD
Pergolide—Speech disorder—Methotrexate—esophageal cancer	0.00223	0.00373	CcSEcCtD
Pergolide—Ear pain—Capecitabine—esophageal cancer	0.0022	0.00366	CcSEcCtD
Pergolide—Thrombophlebitis—Capecitabine—esophageal cancer	0.00216	0.00361	CcSEcCtD
Pergolide—Diabetes mellitus—Capecitabine—esophageal cancer	0.00215	0.00359	CcSEcCtD
Pergolide—Pancreatitis—Cisplatin—esophageal cancer	0.00215	0.00359	CcSEcCtD
Pergolide—Skin discolouration—Methotrexate—esophageal cancer	0.00213	0.00355	CcSEcCtD
Pergolide—Gastroenteritis—Capecitabine—esophageal cancer	0.00211	0.00353	CcSEcCtD
Pergolide—Vascular purpura—Capecitabine—esophageal cancer	0.00209	0.0035	CcSEcCtD
Pergolide—Deafness—Capecitabine—esophageal cancer	0.00209	0.0035	CcSEcCtD
Pergolide—Herpes simplex—Methotrexate—esophageal cancer	0.00209	0.00348	CcSEcCtD
Pergolide—Glossitis—Methotrexate—esophageal cancer	0.00209	0.00348	CcSEcCtD
Pergolide—Eye pain—Capecitabine—esophageal cancer	0.00208	0.00346	CcSEcCtD
Pergolide—Hyperuricaemia—Methotrexate—esophageal cancer	0.00207	0.00346	CcSEcCtD
Pergolide—Libido decreased—Capecitabine—esophageal cancer	0.00202	0.00337	CcSEcCtD
Pergolide—Amnesia—Capecitabine—esophageal cancer	0.00199	0.00333	CcSEcCtD
Pergolide—Increased appetite—Capecitabine—esophageal cancer	0.00199	0.00333	CcSEcCtD
Pergolide—Atrial fibrillation—Capecitabine—esophageal cancer	0.00198	0.0033	CcSEcCtD
Pergolide—Thirst—Capecitabine—esophageal cancer	0.00197	0.00329	CcSEcCtD
Pergolide—Vasculitis—Methotrexate—esophageal cancer	0.00197	0.00329	CcSEcCtD
Pergolide—Dermatitis bullous—Capecitabine—esophageal cancer	0.00196	0.00327	CcSEcCtD
Pergolide—Blood uric acid increased—Methotrexate—esophageal cancer	0.00196	0.00327	CcSEcCtD
Pergolide—Respiratory failure—Methotrexate—esophageal cancer	0.00196	0.00327	CcSEcCtD
Pergolide—Purpura—Capecitabine—esophageal cancer	0.00194	0.00324	CcSEcCtD
Pergolide—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00193	0.00322	CcSEcCtD
Pergolide—Arthritis—Capecitabine—esophageal cancer	0.00193	0.00322	CcSEcCtD
Pergolide—Renal failure—Cisplatin—esophageal cancer	0.00193	0.00321	CcSEcCtD
Pergolide—Vaginal inflammation—Methotrexate—esophageal cancer	0.00192	0.00321	CcSEcCtD
Pergolide—Pulmonary embolism—Methotrexate—esophageal cancer	0.00192	0.00321	CcSEcCtD
Pergolide—Myocardial infarction—Cisplatin—esophageal cancer	0.00192	0.0032	CcSEcCtD
Pergolide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00192	0.0032	CcSEcCtD
Pergolide—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00191	0.00319	CcSEcCtD
Pergolide—Conjunctivitis—Cisplatin—esophageal cancer	0.0019	0.00318	CcSEcCtD
Pergolide—Melaena—Methotrexate—esophageal cancer	0.00188	0.00313	CcSEcCtD
Pergolide—Cystitis noninfective—Methotrexate—esophageal cancer	0.00188	0.00313	CcSEcCtD
Pergolide—Diplopia—Capecitabine—esophageal cancer	0.00187	0.00313	CcSEcCtD
Pergolide—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00186	0.0031	CcSEcCtD
Pergolide—Cystitis—Methotrexate—esophageal cancer	0.00186	0.0031	CcSEcCtD
Pergolide—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00186	0.0031	CcSEcCtD
Pergolide—Migraine—Capecitabine—esophageal cancer	0.00184	0.00308	CcSEcCtD
Pergolide—Vaginal infection—Methotrexate—esophageal cancer	0.00181	0.00303	CcSEcCtD
Pergolide—Face oedema—Capecitabine—esophageal cancer	0.00181	0.00302	CcSEcCtD
Pergolide—Bradycardia—Cisplatin—esophageal cancer	0.00179	0.00299	CcSEcCtD
Pergolide—Cardiac arrest—Capecitabine—esophageal cancer	0.00178	0.00297	CcSEcCtD
Pergolide—Urinary retention—Capecitabine—esophageal cancer	0.00178	0.00297	CcSEcCtD
Pergolide—Mood swings—Capecitabine—esophageal cancer	0.00178	0.00296	CcSEcCtD
Pergolide—Ataxia—Capecitabine—esophageal cancer	0.00176	0.00294	CcSEcCtD
Pergolide—Coma—Methotrexate—esophageal cancer	0.00176	0.00293	CcSEcCtD
Pergolide—Dehydration—Capecitabine—esophageal cancer	0.00174	0.00291	CcSEcCtD
Pergolide—Neoplasm—Methotrexate—esophageal cancer	0.00174	0.0029	CcSEcCtD
Pergolide—Bladder pain—Methotrexate—esophageal cancer	0.00174	0.0029	CcSEcCtD
Pergolide—Liver function test abnormal—Capecitabine—esophageal cancer	0.00173	0.00289	CcSEcCtD
Pergolide—Dry skin—Capecitabine—esophageal cancer	0.00172	0.00287	CcSEcCtD
Pergolide—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00171	0.00286	CcSEcCtD
Pergolide—Pulmonary oedema—Methotrexate—esophageal cancer	0.00171	0.00285	CcSEcCtD
Pergolide—Hypokalaemia—Capecitabine—esophageal cancer	0.00171	0.00285	CcSEcCtD
Pergolide—Visual impairment—Cisplatin—esophageal cancer	0.00169	0.00283	CcSEcCtD
Pergolide—Sepsis—Methotrexate—esophageal cancer	0.00167	0.00278	CcSEcCtD
Pergolide—Gastritis—Capecitabine—esophageal cancer	0.00166	0.00277	CcSEcCtD
Pergolide—Eye disorder—Cisplatin—esophageal cancer	0.00164	0.00274	CcSEcCtD
Pergolide—Tinnitus—Cisplatin—esophageal cancer	0.00164	0.00274	CcSEcCtD
Pergolide—Lymphadenopathy—Methotrexate—esophageal cancer	0.00164	0.00273	CcSEcCtD
Pergolide—Abdominal distension—Capecitabine—esophageal cancer	0.00163	0.00272	CcSEcCtD
Pergolide—Dysphagia—Capecitabine—esophageal cancer	0.00162	0.0027	CcSEcCtD
Pergolide—Asthma—Capecitabine—esophageal cancer	0.00162	0.0027	CcSEcCtD
Pergolide—Influenza—Capecitabine—esophageal cancer	0.00162	0.0027	CcSEcCtD
Pergolide—Thrombophlebitis—Methotrexate—esophageal cancer	0.00161	0.00269	CcSEcCtD
Pergolide—Diabetes mellitus—Methotrexate—esophageal cancer	0.0016	0.00268	CcSEcCtD
Pergolide—Angina pectoris—Capecitabine—esophageal cancer	0.00158	0.00263	CcSEcCtD
Pergolide—Arrhythmia—Cisplatin—esophageal cancer	0.00157	0.00262	CcSEcCtD
Pergolide—Bronchitis—Capecitabine—esophageal cancer	0.00156	0.0026	CcSEcCtD
Pergolide—Alopecia—Cisplatin—esophageal cancer	0.00155	0.00259	CcSEcCtD
Pergolide—Dysuria—Capecitabine—esophageal cancer	0.00151	0.00253	CcSEcCtD
Pergolide—Flatulence—Cisplatin—esophageal cancer	0.00151	0.00252	CcSEcCtD
Pergolide—Weight increased—Capecitabine—esophageal cancer	0.00147	0.00246	CcSEcCtD
Pergolide—Weight decreased—Capecitabine—esophageal cancer	0.00147	0.00244	CcSEcCtD
Pergolide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00146	0.00244	CcSEcCtD
Pergolide—Pneumonia—Capecitabine—esophageal cancer	0.00145	0.00242	CcSEcCtD
Pergolide—Depression—Capecitabine—esophageal cancer	0.00144	0.0024	CcSEcCtD
Pergolide—Tremor—Cisplatin—esophageal cancer	0.00143	0.00239	CcSEcCtD
Pergolide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00142	0.00238	CcSEcCtD
Pergolide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00142	0.00238	CcSEcCtD
Pergolide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00142	0.00237	CcSEcCtD
Pergolide—Renal failure—Capecitabine—esophageal cancer	0.00142	0.00237	CcSEcCtD
Pergolide—Myocardial infarction—Capecitabine—esophageal cancer	0.00142	0.00236	CcSEcCtD
Pergolide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00142	0.00236	CcSEcCtD
Pergolide—Anaemia—Cisplatin—esophageal cancer	0.00142	0.00236	CcSEcCtD
Pergolide—Jaundice—Capecitabine—esophageal cancer	0.00141	0.00235	CcSEcCtD
Pergolide—Urinary tract infection—Capecitabine—esophageal cancer	0.0014	0.00234	CcSEcCtD
Pergolide—Conjunctivitis—Capecitabine—esophageal cancer	0.0014	0.00234	CcSEcCtD
Pergolide—Malaise—Cisplatin—esophageal cancer	0.00138	0.0023	CcSEcCtD
Pergolide—Haematuria—Capecitabine—esophageal cancer	0.00138	0.0023	CcSEcCtD
Pergolide—Leukopenia—Cisplatin—esophageal cancer	0.00137	0.00229	CcSEcCtD
Pergolide—Epistaxis—Capecitabine—esophageal cancer	0.00136	0.00227	CcSEcCtD
Pergolide—Convulsion—Cisplatin—esophageal cancer	0.00133	0.00221	CcSEcCtD
Pergolide—Mood swings—Methotrexate—esophageal cancer	0.00132	0.00221	CcSEcCtD
Pergolide—Bradycardia—Capecitabine—esophageal cancer	0.00132	0.0022	CcSEcCtD
Pergolide—Ataxia—Methotrexate—esophageal cancer	0.00131	0.00219	CcSEcCtD
Pergolide—Myalgia—Cisplatin—esophageal cancer	0.0013	0.00217	CcSEcCtD
Pergolide—Rhinitis—Capecitabine—esophageal cancer	0.0013	0.00217	CcSEcCtD
Pergolide—Anxiety—Cisplatin—esophageal cancer	0.0013	0.00217	CcSEcCtD
Pergolide—Hepatitis—Capecitabine—esophageal cancer	0.0013	0.00216	CcSEcCtD
Pergolide—Liver function test abnormal—Methotrexate—esophageal cancer	0.00129	0.00215	CcSEcCtD
Pergolide—Discomfort—Cisplatin—esophageal cancer	0.00129	0.00215	CcSEcCtD
Pergolide—Pharyngitis—Capecitabine—esophageal cancer	0.00129	0.00215	CcSEcCtD
Pergolide—Oedema peripheral—Capecitabine—esophageal cancer	0.00128	0.00213	CcSEcCtD
Pergolide—Oedema—Cisplatin—esophageal cancer	0.00125	0.00208	CcSEcCtD
Pergolide—Visual impairment—Capecitabine—esophageal cancer	0.00125	0.00208	CcSEcCtD
Pergolide—Infection—Cisplatin—esophageal cancer	0.00124	0.00207	CcSEcCtD
Pergolide—Thrombocytopenia—Cisplatin—esophageal cancer	0.00122	0.00204	CcSEcCtD
Pergolide—Tachycardia—Cisplatin—esophageal cancer	0.00122	0.00203	CcSEcCtD
Pergolide—Eye disorder—Capecitabine—esophageal cancer	0.00121	0.00202	CcSEcCtD
Pergolide—Tinnitus—Capecitabine—esophageal cancer	0.00121	0.00202	CcSEcCtD
Pergolide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00121	0.00202	CcSEcCtD
Pergolide—Asthma—Methotrexate—esophageal cancer	0.00121	0.00201	CcSEcCtD
Pergolide—Eosinophilia—Methotrexate—esophageal cancer	0.00119	0.00199	CcSEcCtD
Pergolide—Anorexia—Cisplatin—esophageal cancer	0.00119	0.00199	CcSEcCtD
Pergolide—Pancreatitis—Methotrexate—esophageal cancer	0.00118	0.00197	CcSEcCtD
Pergolide—Hypotension—Cisplatin—esophageal cancer	0.00117	0.00195	CcSEcCtD
Pergolide—Chills—Capecitabine—esophageal cancer	0.00116	0.00194	CcSEcCtD
Pergolide—Arrhythmia—Capecitabine—esophageal cancer	0.00116	0.00193	CcSEcCtD
Pergolide—Alopecia—Capecitabine—esophageal cancer	0.00115	0.00191	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00114	0.0019	CcSEcCtD
Pergolide—Dysuria—Methotrexate—esophageal cancer	0.00113	0.00188	CcSEcCtD
Pergolide—Paraesthesia—Cisplatin—esophageal cancer	0.00112	0.00187	CcSEcCtD
Pergolide—Dyspnoea—Cisplatin—esophageal cancer	0.00111	0.00186	CcSEcCtD
Pergolide—Flatulence—Capecitabine—esophageal cancer	0.00111	0.00186	CcSEcCtD
Pergolide—Erectile dysfunction—Methotrexate—esophageal cancer	0.00111	0.00185	CcSEcCtD
Pergolide—Dysgeusia—Capecitabine—esophageal cancer	0.00111	0.00184	CcSEcCtD
Pergolide—Back pain—Capecitabine—esophageal cancer	0.00109	0.00182	CcSEcCtD
Pergolide—Decreased appetite—Cisplatin—esophageal cancer	0.00109	0.00181	CcSEcCtD
Pergolide—Pneumonia—Methotrexate—esophageal cancer	0.00108	0.0018	CcSEcCtD
Pergolide—Depression—Methotrexate—esophageal cancer	0.00107	0.00179	CcSEcCtD
Pergolide—Pain—Cisplatin—esophageal cancer	0.00107	0.00178	CcSEcCtD
Pergolide—Tremor—Capecitabine—esophageal cancer	0.00106	0.00176	CcSEcCtD
Pergolide—Renal failure—Methotrexate—esophageal cancer	0.00106	0.00176	CcSEcCtD
Pergolide—Ill-defined disorder—Capecitabine—esophageal cancer	0.00105	0.00175	CcSEcCtD
Pergolide—Conjunctivitis—Methotrexate—esophageal cancer	0.00104	0.00174	CcSEcCtD
Pergolide—Anaemia—Capecitabine—esophageal cancer	0.00104	0.00174	CcSEcCtD
Pergolide—Sweating—Methotrexate—esophageal cancer	0.00103	0.00172	CcSEcCtD
Pergolide—Feeling abnormal—Cisplatin—esophageal cancer	0.00103	0.00172	CcSEcCtD
Pergolide—Haematuria—Methotrexate—esophageal cancer	0.00103	0.00171	CcSEcCtD
Pergolide—Malaise—Capecitabine—esophageal cancer	0.00102	0.0017	CcSEcCtD
Pergolide—Epistaxis—Methotrexate—esophageal cancer	0.00101	0.00169	CcSEcCtD
Pergolide—Vertigo—Capecitabine—esophageal cancer	0.00101	0.00169	CcSEcCtD
Pergolide—Syncope—Capecitabine—esophageal cancer	0.00101	0.00169	CcSEcCtD
Pergolide—Leukopenia—Capecitabine—esophageal cancer	0.00101	0.00169	CcSEcCtD
Pergolide—Palpitations—Capecitabine—esophageal cancer	0.000997	0.00166	CcSEcCtD
Pergolide—Loss of consciousness—Capecitabine—esophageal cancer	0.000992	0.00166	CcSEcCtD
Pergolide—Body temperature increased—Cisplatin—esophageal cancer	0.000988	0.00165	CcSEcCtD
Pergolide—Cough—Capecitabine—esophageal cancer	0.000985	0.00164	CcSEcCtD
Pergolide—Hypertension—Capecitabine—esophageal cancer	0.000974	0.00163	CcSEcCtD
Pergolide—Hepatitis—Methotrexate—esophageal cancer	0.000965	0.00161	CcSEcCtD
Pergolide—Arthralgia—Capecitabine—esophageal cancer	0.000961	0.0016	CcSEcCtD
Pergolide—Chest pain—Capecitabine—esophageal cancer	0.000961	0.0016	CcSEcCtD
Pergolide—Myalgia—Capecitabine—esophageal cancer	0.000961	0.0016	CcSEcCtD
Pergolide—Pharyngitis—Methotrexate—esophageal cancer	0.000958	0.0016	CcSEcCtD
Pergolide—Anxiety—Capecitabine—esophageal cancer	0.000957	0.0016	CcSEcCtD
Pergolide—Discomfort—Capecitabine—esophageal cancer	0.000949	0.00158	CcSEcCtD
Pergolide—Dry mouth—Capecitabine—esophageal cancer	0.00094	0.00157	CcSEcCtD
Pergolide—Visual impairment—Methotrexate—esophageal cancer	0.00093	0.00155	CcSEcCtD
Pergolide—Confusional state—Capecitabine—esophageal cancer	0.000929	0.00155	CcSEcCtD
Pergolide—Oedema—Capecitabine—esophageal cancer	0.000921	0.00154	CcSEcCtD
Pergolide—Infection—Capecitabine—esophageal cancer	0.000915	0.00153	CcSEcCtD
Pergolide—Shock—Capecitabine—esophageal cancer	0.000906	0.00151	CcSEcCtD
Pergolide—Eye disorder—Methotrexate—esophageal cancer	0.000902	0.0015	CcSEcCtD
Pergolide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000902	0.0015	CcSEcCtD
Pergolide—Tinnitus—Methotrexate—esophageal cancer	0.0009	0.0015	CcSEcCtD
Pergolide—Tachycardia—Capecitabine—esophageal cancer	0.000899	0.0015	CcSEcCtD
Pergolide—Asthenia—Cisplatin—esophageal cancer	0.000896	0.0015	CcSEcCtD
Pergolide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00089	0.00149	CcSEcCtD
Pergolide—Anorexia—Capecitabine—esophageal cancer	0.000878	0.00146	CcSEcCtD
Pergolide—Chills—Methotrexate—esophageal cancer	0.000866	0.00144	CcSEcCtD
Pergolide—Hypotension—Capecitabine—esophageal cancer	0.000861	0.00144	CcSEcCtD
Pergolide—Diarrhoea—Cisplatin—esophageal cancer	0.000855	0.00143	CcSEcCtD
Pergolide—Alopecia—Methotrexate—esophageal cancer	0.000853	0.00142	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000839	0.0014	CcSEcCtD
Pergolide—Insomnia—Capecitabine—esophageal cancer	0.000833	0.00139	CcSEcCtD
Pergolide—Paraesthesia—Capecitabine—esophageal cancer	0.000827	0.00138	CcSEcCtD
Pergolide—Dysgeusia—Methotrexate—esophageal cancer	0.000823	0.00137	CcSEcCtD
Pergolide—Dyspnoea—Capecitabine—esophageal cancer	0.000821	0.00137	CcSEcCtD
Pergolide—Back pain—Methotrexate—esophageal cancer	0.000813	0.00136	CcSEcCtD
Pergolide—Dyspepsia—Capecitabine—esophageal cancer	0.000811	0.00135	CcSEcCtD
Pergolide—Decreased appetite—Capecitabine—esophageal cancer	0.000801	0.00134	CcSEcCtD
Pergolide—Vomiting—Cisplatin—esophageal cancer	0.000794	0.00133	CcSEcCtD
Pergolide—Rash—Cisplatin—esophageal cancer	0.000788	0.00131	CcSEcCtD
Pergolide—Pain—Capecitabine—esophageal cancer	0.000788	0.00131	CcSEcCtD
Pergolide—Constipation—Capecitabine—esophageal cancer	0.000788	0.00131	CcSEcCtD
Pergolide—Dermatitis—Cisplatin—esophageal cancer	0.000787	0.00131	CcSEcCtD
Pergolide—Ill-defined disorder—Methotrexate—esophageal cancer	0.000779	0.0013	CcSEcCtD
Pergolide—Anaemia—Methotrexate—esophageal cancer	0.000776	0.0013	CcSEcCtD
Pergolide—Feeling abnormal—Capecitabine—esophageal cancer	0.000759	0.00127	CcSEcCtD
Pergolide—Malaise—Methotrexate—esophageal cancer	0.000758	0.00126	CcSEcCtD
Pergolide—Vertigo—Methotrexate—esophageal cancer	0.000755	0.00126	CcSEcCtD
Pergolide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000753	0.00126	CcSEcCtD
Pergolide—Leukopenia—Methotrexate—esophageal cancer	0.000752	0.00125	CcSEcCtD
Pergolide—Nausea—Cisplatin—esophageal cancer	0.000742	0.00124	CcSEcCtD
Pergolide—Cough—Methotrexate—esophageal cancer	0.000733	0.00122	CcSEcCtD
Pergolide—Body temperature increased—Capecitabine—esophageal cancer	0.000728	0.00121	CcSEcCtD
Pergolide—Abdominal pain—Capecitabine—esophageal cancer	0.000728	0.00121	CcSEcCtD
Pergolide—Convulsion—Methotrexate—esophageal cancer	0.000728	0.00121	CcSEcCtD
Pergolide—Myalgia—Methotrexate—esophageal cancer	0.000715	0.00119	CcSEcCtD
Pergolide—Arthralgia—Methotrexate—esophageal cancer	0.000715	0.00119	CcSEcCtD
Pergolide—Chest pain—Methotrexate—esophageal cancer	0.000715	0.00119	CcSEcCtD
Pergolide—Discomfort—Methotrexate—esophageal cancer	0.000707	0.00118	CcSEcCtD
Pergolide—Confusional state—Methotrexate—esophageal cancer	0.000691	0.00115	CcSEcCtD
Pergolide—Infection—Methotrexate—esophageal cancer	0.000681	0.00114	CcSEcCtD
Pergolide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000671	0.00112	CcSEcCtD
Pergolide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000663	0.00111	CcSEcCtD
Pergolide—Asthenia—Capecitabine—esophageal cancer	0.000661	0.0011	CcSEcCtD
Pergolide—Anorexia—Methotrexate—esophageal cancer	0.000654	0.00109	CcSEcCtD
Pergolide—Pruritus—Capecitabine—esophageal cancer	0.000652	0.00109	CcSEcCtD
Pergolide—Hypotension—Methotrexate—esophageal cancer	0.000641	0.00107	CcSEcCtD
Pergolide—Diarrhoea—Capecitabine—esophageal cancer	0.00063	0.00105	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000625	0.00104	CcSEcCtD
Pergolide—Insomnia—Methotrexate—esophageal cancer	0.00062	0.00103	CcSEcCtD
Pergolide—Paraesthesia—Methotrexate—esophageal cancer	0.000616	0.00103	CcSEcCtD
Pergolide—Dyspnoea—Methotrexate—esophageal cancer	0.000611	0.00102	CcSEcCtD
Pergolide—Somnolence—Methotrexate—esophageal cancer	0.00061	0.00102	CcSEcCtD
Pergolide—Dizziness—Capecitabine—esophageal cancer	0.000609	0.00102	CcSEcCtD
Pergolide—Dyspepsia—Methotrexate—esophageal cancer	0.000604	0.00101	CcSEcCtD
Pergolide—Decreased appetite—Methotrexate—esophageal cancer	0.000596	0.000995	CcSEcCtD
Pergolide—Pain—Methotrexate—esophageal cancer	0.000586	0.000978	CcSEcCtD
Pergolide—Vomiting—Capecitabine—esophageal cancer	0.000586	0.000977	CcSEcCtD
Pergolide—Rash—Capecitabine—esophageal cancer	0.000581	0.000969	CcSEcCtD
Pergolide—Dermatitis—Capecitabine—esophageal cancer	0.00058	0.000968	CcSEcCtD
Pergolide—Headache—Capecitabine—esophageal cancer	0.000577	0.000963	CcSEcCtD
Pergolide—Feeling abnormal—Methotrexate—esophageal cancer	0.000565	0.000943	CcSEcCtD
Pergolide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000561	0.000936	CcSEcCtD
Pergolide—Nausea—Capecitabine—esophageal cancer	0.000547	0.000913	CcSEcCtD
Pergolide—Abdominal pain—Methotrexate—esophageal cancer	0.000542	0.000904	CcSEcCtD
Pergolide—Body temperature increased—Methotrexate—esophageal cancer	0.000542	0.000904	CcSEcCtD
Pergolide—Asthenia—Methotrexate—esophageal cancer	0.000492	0.000821	CcSEcCtD
Pergolide—Pruritus—Methotrexate—esophageal cancer	0.000485	0.000809	CcSEcCtD
Pergolide—Diarrhoea—Methotrexate—esophageal cancer	0.000469	0.000783	CcSEcCtD
Pergolide—Dizziness—Methotrexate—esophageal cancer	0.000453	0.000757	CcSEcCtD
Pergolide—Vomiting—Methotrexate—esophageal cancer	0.000436	0.000727	CcSEcCtD
Pergolide—Rash—Methotrexate—esophageal cancer	0.000432	0.000721	CcSEcCtD
Pergolide—Dermatitis—Methotrexate—esophageal cancer	0.000432	0.000721	CcSEcCtD
Pergolide—Headache—Methotrexate—esophageal cancer	0.00043	0.000717	CcSEcCtD
Pergolide—Nausea—Methotrexate—esophageal cancer	0.000407	0.00068	CcSEcCtD
Pergolide—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	4.04e-05	0.000101	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KDR—esophageal cancer	4e-05	9.99e-05	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—TP53—esophageal cancer	3.99e-05	9.97e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.99e-05	9.96e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—EGFR—esophageal cancer	3.99e-05	9.95e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	3.99e-05	9.95e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	3.97e-05	9.9e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	3.96e-05	9.88e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KDR—esophageal cancer	3.94e-05	9.84e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CYP1B1—esophageal cancer	3.93e-05	9.82e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—NOS3—esophageal cancer	3.9e-05	9.74e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	3.9e-05	9.73e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—PIK3CA—esophageal cancer	3.89e-05	9.72e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	3.89e-05	9.7e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	3.88e-05	9.68e-05	CbGpPWpGaD
Pergolide—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.86e-05	9.63e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.84e-05	9.59e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—ERBB2—esophageal cancer	3.82e-05	9.54e-05	CbGpPWpGaD
Pergolide—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	3.81e-05	9.51e-05	CbGpPWpGaD
Pergolide—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	3.81e-05	9.51e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.81e-05	9.5e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HIF1A—esophageal cancer	3.8e-05	9.48e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	3.77e-05	9.41e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	3.74e-05	9.33e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	3.72e-05	9.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	3.71e-05	9.27e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CYP19A1—esophageal cancer	3.7e-05	9.23e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—NOS3—esophageal cancer	3.68e-05	9.18e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—MYC—esophageal cancer	3.67e-05	9.16e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—NOS3—esophageal cancer	3.66e-05	9.14e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	3.66e-05	9.14e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	3.66e-05	9.14e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	3.65e-05	9.11e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KDR—esophageal cancer	3.63e-05	9.07e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—NOS3—esophageal cancer	3.63e-05	9.06e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	3.63e-05	9.06e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GNG7—esophageal cancer	3.62e-05	9.04e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	3.6e-05	8.98e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—EGFR—esophageal cancer	3.59e-05	8.96e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KDR—esophageal cancer	3.58e-05	8.92e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	3.53e-05	8.82e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	3.52e-05	8.78e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—CCND1—esophageal cancer	3.51e-05	8.75e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	3.51e-05	8.75e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KDR—esophageal cancer	3.5e-05	8.74e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	3.47e-05	8.67e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	3.46e-05	8.63e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	3.46e-05	8.63e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	3.46e-05	8.62e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—ERBB2—esophageal cancer	3.44e-05	8.59e-05	CbGpPWpGaD
Pergolide—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.44e-05	8.58e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—CCND1—esophageal cancer	3.43e-05	8.57e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	3.42e-05	8.54e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	3.42e-05	8.54e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	3.4e-05	8.49e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—ERBB2—esophageal cancer	3.4e-05	8.48e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	3.4e-05	8.48e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.39e-05	8.47e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	3.39e-05	8.46e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—CCND1—esophageal cancer	3.38e-05	8.43e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.37e-05	8.42e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	3.37e-05	8.41e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	3.37e-05	8.4e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	3.36e-05	8.39e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PTGS2—esophageal cancer	3.35e-05	8.36e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—CREBBP—esophageal cancer	3.32e-05	8.29e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	3.32e-05	8.29e-05	CbGpPWpGaD
Pergolide—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.32e-05	8.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	3.31e-05	8.26e-05	CbGpPWpGaD
Pergolide—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.3e-05	8.24e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	3.3e-05	8.23e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	3.28e-05	8.18e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	3.27e-05	8.16e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KDR—esophageal cancer	3.25e-05	8.12e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.24e-05	8.08e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.23e-05	8.06e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—EP300—esophageal cancer	3.23e-05	8.05e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—CCND1—esophageal cancer	3.22e-05	8.05e-05	CbGpPWpGaD
Pergolide—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.21e-05	8.02e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.19e-05	7.96e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NOS3—esophageal cancer	3.16e-05	7.9e-05	CbGpPWpGaD
Pergolide—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.16e-05	7.89e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—EP300—esophageal cancer	3.16e-05	7.89e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NOS3—esophageal cancer	3.15e-05	7.86e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	3.12e-05	7.79e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	3.12e-05	7.79e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—PIK3CA—esophageal cancer	3.12e-05	7.78e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—EP300—esophageal cancer	3.11e-05	7.76e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CREBBP—esophageal cancer	3.1e-05	7.75e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	3.07e-05	7.65e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	3.06e-05	7.65e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	3.06e-05	7.64e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	3.05e-05	7.62e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—EGFR—esophageal cancer	3.05e-05	7.61e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—CCND1—esophageal cancer	3.04e-05	7.59e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ENO1—esophageal cancer	3.02e-05	7.55e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.02e-05	7.55e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—TP53—esophageal cancer	3.02e-05	7.52e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	3.01e-05	7.52e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	3.01e-05	7.52e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	3e-05	7.49e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—CCND1—esophageal cancer	3e-05	7.49e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	3e-05	7.49e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	3e-05	7.48e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	2.99e-05	7.46e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PSME2—esophageal cancer	2.98e-05	7.44e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PSME1—esophageal cancer	2.98e-05	7.44e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—NOS3—esophageal cancer	2.97e-05	7.42e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—EP300—esophageal cancer	2.97e-05	7.41e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	2.96e-05	7.39e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	2.94e-05	7.35e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	2.94e-05	7.34e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	2.94e-05	7.33e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.92e-05	7.28e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.91e-05	7.27e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	2.9e-05	7.24e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	2.9e-05	7.24e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	2.87e-05	7.16e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.87e-05	7.16e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	2.86e-05	7.15e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	2.82e-05	7.04e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—MYC—esophageal cancer	2.81e-05	7.02e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.81e-05	7.01e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EP300—esophageal cancer	2.8e-05	6.99e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—EP300—esophageal cancer	2.79e-05	6.95e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NOS3—esophageal cancer	2.78e-05	6.93e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	2.78e-05	6.93e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EP300—esophageal cancer	2.76e-05	6.89e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EP300—esophageal cancer	2.76e-05	6.89e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—MYC—esophageal cancer	2.75e-05	6.87e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—EGFR—esophageal cancer	2.75e-05	6.87e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NOS3—esophageal cancer	2.73e-05	6.82e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	2.73e-05	6.81e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTGS2—esophageal cancer	2.72e-05	6.79e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—MYC—esophageal cancer	2.71e-05	6.76e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	2.71e-05	6.76e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—EGFR—esophageal cancer	2.69e-05	6.72e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	2.68e-05	6.68e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—EGFR—esophageal cancer	2.65e-05	6.61e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	2.65e-05	6.61e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	2.62e-05	6.54e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CCND1—esophageal cancer	2.62e-05	6.53e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.61e-05	6.51e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.6e-05	6.5e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CCND1—esophageal cancer	2.6e-05	6.49e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—ERBB2—esophageal cancer	2.6e-05	6.49e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—MYC—esophageal cancer	2.59e-05	6.46e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.57e-05	6.42e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	2.56e-05	6.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.55e-05	6.36e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	2.53e-05	6.32e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—EGFR—esophageal cancer	2.53e-05	6.31e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	2.53e-05	6.31e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	2.52e-05	6.28e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	2.5e-05	6.25e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EP300—esophageal cancer	2.49e-05	6.22e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	2.49e-05	6.22e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	2.49e-05	6.21e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	2.45e-05	6.11e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MYC—esophageal cancer	2.44e-05	6.09e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.42e-05	6.03e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	2.41e-05	6.01e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EP300—esophageal cancer	2.41e-05	6.01e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—esophageal cancer	2.41e-05	6.01e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—esophageal cancer	2.41e-05	6.01e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EP300—esophageal cancer	2.39e-05	5.98e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	2.39e-05	5.96e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EGFR—esophageal cancer	2.39e-05	5.95e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.37e-05	5.91e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—esophageal cancer	2.35e-05	5.88e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	2.35e-05	5.88e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	2.34e-05	5.83e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EP300—esophageal cancer	2.33e-05	5.81e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	2.33e-05	5.81e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—esophageal cancer	2.31e-05	5.76e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	2.3e-05	5.74e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—esophageal cancer	2.3e-05	5.73e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EP300—esophageal cancer	2.29e-05	5.72e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—EP300—esophageal cancer	2.26e-05	5.65e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—esophageal cancer	2.26e-05	5.64e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—esophageal cancer	2.26e-05	5.64e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—esophageal cancer	2.23e-05	5.55e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	2.22e-05	5.54e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	2.21e-05	5.52e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.21e-05	5.51e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	2.2e-05	5.48e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	2.19e-05	5.45e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—esophageal cancer	2.17e-05	5.42e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.16e-05	5.4e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	2.14e-05	5.34e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	2.13e-05	5.3e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—esophageal cancer	2.12e-05	5.3e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.12e-05	5.29e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EP300—esophageal cancer	2.11e-05	5.27e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—esophageal cancer	2.1e-05	5.24e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—esophageal cancer	2.09e-05	5.21e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EP300—esophageal cancer	2.08e-05	5.19e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	2.07e-05	5.17e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—esophageal cancer	2.06e-05	5.14e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	2.06e-05	5.13e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—esophageal cancer	2.05e-05	5.12e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	2.04e-05	5.1e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	2.04e-05	5.1e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—esophageal cancer	2.04e-05	5.09e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EP300—esophageal cancer	2.04e-05	5.08e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—esophageal cancer	2.03e-05	5.07e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—esophageal cancer	2e-05	5e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—esophageal cancer	2e-05	4.99e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.99e-05	4.96e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	1.99e-05	4.95e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—esophageal cancer	1.98e-05	4.93e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—esophageal cancer	1.98e-05	4.93e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	1.95e-05	4.88e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—NOS3—esophageal cancer	1.94e-05	4.84e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.89e-05	4.72e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.84e-05	4.6e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—esophageal cancer	1.84e-05	4.6e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.81e-05	4.52e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.8e-05	4.5e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.78e-05	4.45e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.78e-05	4.44e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.77e-05	4.43e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.77e-05	4.42e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.77e-05	4.42e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.77e-05	4.42e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.74e-05	4.33e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.72e-05	4.3e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.72e-05	4.3e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.71e-05	4.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	1.7e-05	4.23e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.67e-05	4.18e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.67e-05	4.16e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.65e-05	4.11e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—esophageal cancer	1.64e-05	4.09e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.61e-05	4.02e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.56e-05	3.9e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.54e-05	3.84e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—esophageal cancer	1.51e-05	3.77e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.51e-05	3.76e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.49e-05	3.71e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—EP300—esophageal cancer	1.47e-05	3.68e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.46e-05	3.64e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.42e-05	3.53e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.4e-05	3.49e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.35e-05	3.38e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—NOS3—esophageal cancer	1.27e-05	3.16e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.16e-05	2.89e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.09e-05	2.72e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—EP300—esophageal cancer	9.64e-06	2.41e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—esophageal cancer	7.13e-06	1.78e-05	CbGpPWpGaD
